Participated · Series C · May 2026

Butterfly Medical develops the Butterfly® prostatic retraction device, a minimally invasive, implantable solution intended to mechanically retract the lateral lobes of the prostate to restore urine flow. The device has secured CE Mark certification for use in Europe and is not yet approved in the U.S., where it remains limited to investigational use. The company recently completed a pivotal trial and is pursuing U.S. regulatory filings as it prepares for commercialization. Management emphasized the platform's clinical data, ease of use, competitive cost of goods sold and lack of durable capital equipment as advantages for adoption. Leadership also noted that the company has advanced to a stage comparable to other minimally invasive BPH solutions while deploying significantly less capital. Butterfly plans to present its clinical progress publicly at AUA 2026 as part of its commercialization push.

Led · Series A · Feb 2026

Avisi Technologies, Inc. is a clinical-stage company focused on creating novel ophthalmic solutions, most notably VisiPlate®, an investigational aqueous shunt engineered from an ultrathin, patented metamaterial designed to maintain intra-ocular pressure through multiple microchannels that resist blockage and scarring. The device targets the unmet need for long-term, low-maintenance glaucoma care and is currently being evaluated in the FDA IDE-approved SAPPHIRE pivotal trial that is enrolling patients across the United States. Avisi’s broader pipeline includes V-001, a sustained intraocular drug-delivery platform, and VisiPlate-S, a drainage device intended for use during cataract surgery. Proceeds from its latest financing will fund the SAPPHIRE trial and advance additional pipeline programs addressing the full spectrum of glaucomatous disease. The company has garnered recognition and non-dilutive support from the National Science Foundation, the Glaucoma Research Foundation, Johnson & Johnson JLABS, and other industry accelerators. Current investors include both venture funds and angel networks, underscoring diversified backing for its development roadmap. No revenue or user figures have been disclosed to date.

Participated · Series B · Feb 2026

Founded in 2023 and headquartered in Osaka, Japan, A-wave focuses on digital medical technologies for the growing population of chronic heart-failure patients. Its flagship product is an at-home monitoring system that applies cardiology specialist diagnostic know-how to continuously track patient condition and flag deterioration triggered by excess salt intake, overwork, or other stressors. The company aims to establish a medical framework that enables early intervention and thereby lowers rehospitalization rates. Proceeds from its latest funding will finance a nationwide clinical trial of the device in partnership with multiple Japanese medical institutions. Insights from the trial will be used to refine the system and prepare it for practical commercialization. A-wave also plans to deepen collaborations with relevant academic societies and healthcare providers to build a robust deployment ecosystem. No revenue or user metrics have been disclosed to date.

Led · Series A · Feb 2026

Quali is a medical-robotics company focused on creating robots that support and enhance microsurgical procedures, a field that demands extremely delicate and highly skilled work under a microscope. By inheriting technology cultivated within the Sony Group’s medical robotics research, the startup is engineering products aimed at improving surgical precision, safety, and overall patient quality of life. The company’s overarching goal is to enable broader access to microsurgery by reducing the skill barrier for surgeons and facilitating the social implementation of advanced surgical technologies. Funds from its recent Series A round will be directed toward accelerating product development and clinical readiness of its microsurgery support robots. Quali positions its technology as a solution to the shortage of experienced microsurgeons and aims to integrate its systems into clinical settings worldwide. The firm’s current financial highlight is the ¥1.8 billion it secured in Series A equity financing, although no revenue or user metrics have yet been disclosed.

Participated · Series B · Apr 2023

SentiAR develops augmented reality visualization technology for medical procedures, centered on its CommandEP product that creates real-time 3D holographic views of patient anatomy. CommandEP integrates existing imaging systems and uses a headset to provide hands-free manipulation of patient data and live catheter locations during cardiac ablation. The system gives physicians a 360-degree interactive view of heart anatomy and has been shown to improve navigation accuracy in the heart by up to 50%. The company says the new funding will support additional partnerships and wider clinical deployments of CommandEP. SentiAR is based in St. Louis, Missouri, and positions its technology as a workflow-friendly AR tool designed not to impede clinical procedures. The company highlights clinical and strategic collaborations as central to its commercialization plans. SentiAR develops a mixed-reality visualization platform for use during interventional procedures, beginning with cardiac ablation and treatment of atrial fibrillation. Its FDA 510(k) cleared CommandEP system receives imaging data from electroanatomic mapping systems and creates a 3D holographic image via proprietary data-flow and visualization algorithms. The patented system displays real-time catheter positions in the patient’s heart through a wearable headset and relies on a custom AR engine for performance. SentiAR’s technology was spun out of Washington University in St. Louis by Dr. Jennifer Silva and Dr. Jonathan Silva. Led by CEO Berk Tas, the company plans to use new funding to accelerate innovation on the CommandEP system.